Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 5/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 3/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw441756X SCHEMBL29516594 | 1.00 | KMT2A (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| Gw441756X SCHEMBL29794620 | 1.00 | KMT2A (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| Gw441756X SCHEMBL16196749 | 1.00 | KMT2A (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| Gw441756X SCHEMBL5787774 | 1.00 | KMT2A (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| Gw441756X SCHEMBL29435064 | 1.00 | KMT2A (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| SCHEMBL5788846 | 0.82 | NTRK1 (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| SCHEMBL5788840 | 0.82 | NTRK1 (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| SCHEMBL5469776 | 0.82 | NTRK1 (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| SCHEMBL14448833 | 0.82 | NTRK1 (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 | |
| SCHEMBL5469785 | 0.82 | NTRK1 (1.00) | KMT2AMEN1NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430053-B1 | AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN | SMITHKLINE BEECHAM CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-20060128745-A1 | Chemical compounds | LACKEY KAREN E | 2006-06-15 | — | — | US | claimed |
| US-7015231-B2 | such as (3Z)-3-[(1-methyl-1H-indol-3-yl)methylene]-1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one; tyrosine kinase inhibitors; for treatment of tumor growth, restenosis, atherosclerosis, pain and thrombosis | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| US-20040198766-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | claimed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186400-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12268666-B2 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | LOXO ONCOLOGY, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12109193-B2 | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | LOXO ONCOLOGY INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-12102621-B2 | Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240238253-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20150073036-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150073036-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150073036-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2014071358-A2 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-1430053-B1 | AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN | SMITHKLINE BEECHAM CORP (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060128745-A1 | Chemical compounds | LACKEY KAREN E | 2006-06-15 | — | — | US | disclosed |
| US-7015231-B2 | such as (3Z)-3-[(1-methyl-1H-indol-3-yl)methylene]-1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one; tyrosine kinase inhibitors; for treatment of tumor growth, restenosis, atherosclerosis, pain and thrombosis | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-21 | — | — | US | disclosed |
| US-20040198766-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073036-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | KMT2A 4101/4885MEN1 3237/4885NTRK1 1/4885 |
| US-20040198766-A1 | Chemical compounds | FRK, LTK, TXK | KMT2A 2284/4885MEN1 4466/4885NTRK1 56/4885 |
| US-20240238253-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | API5, IL5, SRMS | KMT2A 247/4885MEN1 277/4885NTRK1 2757/4885 |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | KMT2A 540/4885MEN1 306/4885NTRK1 22/4885 |
| US-20250186400-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | API5, IL5, SRMS | KMT2A 247/4885MEN1 277/4885NTRK1 2757/4885 |
| US-12268666-B2 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | API5, IL5, SRMS | KMT2A 247/4885MEN1 277/4885NTRK1 2757/4885 |
| US-12109193-B2 | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | API5, IL5, SRMS | KMT2A 222/4885MEN1 250/4885NTRK1 2731/4885 |
| US-20060128745-A1 | Chemical compounds | FRK, LCK, LTK | KMT2A 1636/4885MEN1 4500/4885NTRK1 53/4885 |
| US-12102621-B2 | Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | KMT2A 520/4885MEN1 365/4885NTRK1 24/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | KMT2A 562/4885MEN1 483/4885NTRK1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.